FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210342811> ?p ?o ?g. }

• W3210342811 abstract "Early response could be obtained in most patients with relapsed or refractory B cell lymphoblastic leukemia (R/R B-ALL) treated with chimeric antigen receptor T-cell (CAR-T) therapy, but relapse occurs in some patients. There is no consensus on treatment strategy post CAR-T cell therapy. In this retrospective study of humanized CD19-targeted CAR-T cell (hCART19s) therapy for R/R B-ALL, we analyzed the patients treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) or received a second hCART19s infusion, and summarized their efficacy and safety. We retrospectively studied 28 R/R B-ALL patients treated with hCART19s in the Affiliated Hospital of Xuzhou Medical University from 2016 to 2020. After the first hCART19s infusion, 10 patients received allo-HSCT (CART+HSCT group), 7 patients received a second hCART19s infusion (CART2 group), and 11 patients did not receive HSCT or a second hCART19s infusion (CART1 group). The safety, efficacy, and long-term survival were analyzed. Of the 28 patients who received hCART19s treatment, 1 patient could not be evaluated for efficacy, and 25 (92.6%) achieved complete remission (CR) with 20 (74.7%) achieving minimal residual disease (MRD) negativity. Seven (25%) patients experienced grade 3-4 CRS, and one died from grade 5 CRS. No patient experienced ≥3 grade ICANS. The incidence of second CR is higher in the CART+HSCT group compared to the CART2 group (100% vs. 42.9%, p=0.015). The median follow-up time was 1,240 days (range: 709-1,770). Significantly longer overall survival (OS) and leukemia-free survival (LFS) were achieved in the CART+HSCT group (median OS and LFS: not reached, p=0.006 and 0.001, respectively) compared to the CART2 group (median OS: 482; median LFS: 189) and the CART1 group (median OS: 236; median LFS: 35). In the CART+HSCT group, the incidence of acute graft-versus-host disease (aGVHD) was 30% (3/10), and transplantation-related mortality was 30% (3/10). No chronic GVHD occurred. Multivariate analysis results showed that blasts ≥ 20% in the bone marrow and MRD ≥ 65.6% are independent factors for inferior OS and LFS, respectively, while receiving allo-HSCT is an independent factor associated with both longer OS and LFS. In conclusion, early allo-HSCT after CAR-T therapy can achieve long-term efficacy, and the adverse events are controllable." @default.
• W3210342811 created "2021-11-08" @default.
• W3210342811 creator A5000930830 @default.
• W3210342811 creator A5001560024 @default.
• W3210342811 creator A5011564905 @default.
• W3210342811 creator A5020955864 @default.
• W3210342811 creator A5022581561 @default.
• W3210342811 creator A5023393797 @default.
• W3210342811 creator A5026818586 @default.
• W3210342811 creator A5031022736 @default.
• W3210342811 creator A5032218589 @default.
• W3210342811 creator A5032808067 @default.
• W3210342811 creator A5045094860 @default.
• W3210342811 creator A5048129965 @default.
• W3210342811 creator A5050692462 @default.
• W3210342811 creator A5059685266 @default.
• W3210342811 creator A5067016617 @default.
• W3210342811 creator A5068990085 @default.
• W3210342811 creator A5073386987 @default.
• W3210342811 creator A5074529705 @default.
• W3210342811 creator A5087585195 @default.
• W3210342811 date "2021-10-29" @default.
• W3210342811 modified "2023-10-17" @default.
• W3210342811 title "Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy" @default.
• W3210342811 cites W1987446594 @default.
• W3210342811 cites W2066886754 @default.
• W3210342811 cites W2099570622 @default.
• W3210342811 cites W2129702476 @default.
• W3210342811 cites W2141019574 @default.
• W3210342811 cites W2143034151 @default.
• W3210342811 cites W2179454156 @default.
• W3210342811 cites W2613659662 @default.
• W3210342811 cites W2787621143 @default.
• W3210342811 cites W2796821082 @default.
• W3210342811 cites W2911504656 @default.
• W3210342811 cites W2962839079 @default.
• W3210342811 cites W2965223724 @default.
• W3210342811 cites W2985909236 @default.
• W3210342811 cites W3016727307 @default.
• W3210342811 cites W3021616332 @default.
• W3210342811 cites W3030279047 @default.
• W3210342811 cites W3043222210 @default.
• W3210342811 cites W3080130807 @default.
• W3210342811 cites W3087218907 @default.
• W3210342811 cites W3088453061 @default.
• W3210342811 cites W3094048574 @default.
• W3210342811 cites W3133320237 @default.
• W3210342811 cites W3190750448 @default.
• W3210342811 doi "https://doi.org/10.3389/fimmu.2021.755549" @default.
• W3210342811 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8586453" @default.
• W3210342811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34777367" @default.
• W3210342811 hasPublicationYear "2021" @default.
• W3210342811 type Work @default.
• W3210342811 sameAs 3210342811 @default.
• W3210342811 citedByCount "8" @default.
• W3210342811 countsByYear W32103428112022 @default.
• W3210342811 countsByYear W32103428112023 @default.
• W3210342811 crossrefType "journal-article" @default.
• W3210342811 hasAuthorship W3210342811A5000930830 @default.
• W3210342811 hasAuthorship W3210342811A5001560024 @default.
• W3210342811 hasAuthorship W3210342811A5011564905 @default.
• W3210342811 hasAuthorship W3210342811A5020955864 @default.
• W3210342811 hasAuthorship W3210342811A5022581561 @default.
• W3210342811 hasAuthorship W3210342811A5023393797 @default.
• W3210342811 hasAuthorship W3210342811A5026818586 @default.
• W3210342811 hasAuthorship W3210342811A5031022736 @default.
• W3210342811 hasAuthorship W3210342811A5032218589 @default.
• W3210342811 hasAuthorship W3210342811A5032808067 @default.
• W3210342811 hasAuthorship W3210342811A5045094860 @default.
• W3210342811 hasAuthorship W3210342811A5048129965 @default.
• W3210342811 hasAuthorship W3210342811A5050692462 @default.
• W3210342811 hasAuthorship W3210342811A5059685266 @default.
• W3210342811 hasAuthorship W3210342811A5067016617 @default.
• W3210342811 hasAuthorship W3210342811A5068990085 @default.
• W3210342811 hasAuthorship W3210342811A5073386987 @default.
• W3210342811 hasAuthorship W3210342811A5074529705 @default.
• W3210342811 hasAuthorship W3210342811A5087585195 @default.
• W3210342811 hasBestOaLocation W32103428111 @default.
• W3210342811 hasConcept C121332964 @default.
• W3210342811 hasConcept C121608353 @default.
• W3210342811 hasConcept C126322002 @default.
• W3210342811 hasConcept C141071460 @default.
• W3210342811 hasConcept C142424586 @default.
• W3210342811 hasConcept C143998085 @default.
• W3210342811 hasConcept C167135981 @default.
• W3210342811 hasConcept C2777408962 @default.
• W3210342811 hasConcept C2777701055 @default.
• W3210342811 hasConcept C2911091166 @default.
• W3210342811 hasConcept C3875195 @default.
• W3210342811 hasConcept C71924100 @default.
• W3210342811 hasConcept C87355193 @default.
• W3210342811 hasConcept C90924648 @default.
• W3210342811 hasConceptScore W3210342811C121332964 @default.
• W3210342811 hasConceptScore W3210342811C121608353 @default.
• W3210342811 hasConceptScore W3210342811C126322002 @default.
• W3210342811 hasConceptScore W3210342811C141071460 @default.
• W3210342811 hasConceptScore W3210342811C142424586 @default.
• W3210342811 hasConceptScore W3210342811C143998085 @default.
• W3210342811 hasConceptScore W3210342811C167135981 @default.
• W3210342811 hasConceptScore W3210342811C2777408962 @default.

• next